3-(9H-fluoren-4-yloxy)-1-{[2-(2-methoxyphenoxy)-ethyl]amino}-2-propanol | 1479050-04-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 3-(9H-fluoren-4-yloxy)-1-{[2-(2-methoxyphenoxy)-ethyl]amino}-2-propanol
• 英文别名: 1-(9H-fluoren-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
• CAS: 1479050-04-8
• 化学式: C₂₅H₂₇NO₄
• 分子量: 405.494
• InChiKey: YIQGJWJWWIQLJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  30
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  60
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-羟基芴-9-酮 在 potassium hydroxide 、 sodium hydroxide 、 肼 作用下， 以 乙二醇 、 二甲基亚砜 、 异丙醇 为溶剂， 生成 3-(9H-fluoren-4-yloxy)-1-{[2-(2-methoxyphenoxy)-ethyl]amino}-2-propanol
  参考文献：
  名称：

  Novel Carvedilol Analogues That Suppress Store-Overload-Induced Ca²⁺ Release

  摘要：

  Carvedilol is a uniquely effective drug for the treatment of cardiac arrhythmias in patients with heart failure. This activity is in part because of its ability to inhibit store-overload-induced calcium release (SOICR) through the RyR2 channel. We describe the synthesis, characterization, and bioassay of ca. 100 compounds based on the carvedilol motif to identify features that correlate with and optimize SOICR inhibition. A single-cell bioassay was employed on the basis of the RyR2-R4496C mutant HEK-293 cell line in which calcium release from the endoplasmic reticulum through the defective channel was measured. IC50 values for SOICR inhibition were thus obtained. The compounds investigated contained modifications to the three principal subunits of carvedilol, including the carbazole and catechol moieties, as well as the linker chain containing the beta-amino alcohol functionality. The SAR results indicate that significant alterations are tolerated in each of the three subunits.

  DOI：

  10.1021/jm401090a

文献信息

• [EN] STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME<br/>[FR] INHIBITEURS DE LIBÉRATION DU CALCIUM INDUITE PAR UNE SURCHARGE DU STOCK CALCIQUE ET LEURS MÉTHODES DE PRODUCTION ET D'UTILISATION
  申请人：UTI LIMITED PARTNERSHIP

  公开号：WO2015031914A1

  公开（公告）日：2015-03-05

  The present invention provides compounds having store overload-induced Ca2+ release (SOICR) inhibitory activity and methods for producing and using the same. In particular, compounds of the invention is of the formula: R1-X1-L-X2-R2, wherein R1, X1, L, X2, and R2 are those defined herein.

  本发明提供了具有存储过载诱导的Ca2+释放（SOICR）抑制活性的化合物以及生产和使用这些化合物的方法。特别是，本发明的化合物具有如下通式：R1-X1-L-X2-R2，其中R1、X1、L、X2和R2如本文所定义。
• Crystalline forms of carvedilol and processes for their preparation
  申请人：Lifshitz Igor

  公开号：US20070043099A1

  公开（公告）日：2007-02-22

  This invention relates to a novel crystalline form of carvedilol, to processes for its preparation, to compositions containing it and to its use in medicine. This invention further relates to a novel process for preparing crystalline carvedilol Form II.
• Therapeutic Combinations Useful in Treating CFTR Related Diseases
  申请人：Singh Ashvani

  公开号：US20110177999A1

  公开（公告）日：2011-07-21

  The present invention relates to therapeutic combinations and kits useful in treating CFTR-related diseases, such as cystic fibrosis.
• STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME
  申请人：BACK Tom

  公开号：US20160214973A1

  公开（公告）日：2016-07-28

  The present invention provides compounds having store overload-induced Ca 2+ release (SOICR) inhibitory activity and methods for producing and using the same. In particular, compounds of the invention is of the formula: R 1 —X 1 -L-X 2 —R 2 , wherein R 1 , X 1 , L, X 2 , and R 2 are those defined herein.
• US7482471B2
  申请人：——

  公开号：US7482471B2

  公开（公告）日：2009-01-27